ARDELYX, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
ARDELYX, INC. (ARDX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -0.60% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2025-02-20
- ARDELYX, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was -0.60%.
- ARDELYX, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was -1.70%.
- ARDELYX, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was -1.50%, a 250.00% decline from fiscal 2021.
- ARDELYX, INC. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 1.00%, a 23.08% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -0.60% 10-K · filed 2025-02-20 | |
| 2023-12-31 | -1.70% 10-K · filed 2025-02-20 | 1.70% 10-K · filed 2024-02-22 |
| 2022-12-31 | -1.50% 10-K · filed 2025-02-20 | 1.50% 10-K · filed 2023-03-02 |
| 2021-12-31 | 1.00% 10-K · filed 2024-02-22 | |
| 2020-12-31 | 1.30% 10-K · filed 2023-03-02 | |
| 2019-12-31 | 1.60% 10-K · filed 2022-02-28 | |
| 2018-12-31 | 1.40% 10-K · filed 2021-03-08 | |
| 2017-12-31 | 1.00% 10-K · filed 2020-03-06 | |
| 2016-12-31 | 0.30% 10-K · filed 2019-03-06 | |
| 2015-12-31 | 1.30% 10-K · filed 2018-03-14 | |
| 2013-12-31 | 7.30% 10-K · filed 2016-03-04 | |
| 2012-12-31 | 4.40% 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |